For the first time, Israel treated patients who suffered from post-traumatic stress disorder with MDMA-assisted psychotherapy in February of this year. This was part of the Phase 3 trials of MDMA, which are a part of a research initiative being carried out in collaboration with the Multidisciplinary Association for Psychedelic Studies (“MAPS”), which is based in the United States. This initiative encompasses 15 sites in Israel, Canada and the U.S. and is expected to end in the last quarter of next year. The body anticipates that it will receive full regulatory approval from the FDA.
The first trial that was conducted on MDMA attained an 83% rate of success in PTSD-symptom alleviation. Its results, which were reported in 2010, showed that the treatment outcomes were sustained throughout the duration of the study. Recent studies have shown that MDMA produces much better therapeutic results in comparison with FDA-approved drugs for PTSD. This led to the FDA…
About PsychedelicNewsWire
PsychedelicNewsWire (PNW) is a specialized content distribution company that (1) aggregates and distributes news and information on the latest developments in all aspects and advances of psychedelics and their use, (2) creates PsychedelicNewsBreaks designed to quickly update investors on important industry news, (3) leverages a team of expert editors to enhance press releases for maximum impact, (4) assists companies with the management and optimization of social media across a range of platforms, and (5) delivers unparalleled corporate communication solutions. PNW stays abreast of the latest information and has established a reputation as the go to source for coverage of psychedelics, therapeutics and emerging market opportunities. Our team of seasoned journalists has a proven track record of helping both public and private companies gain traction with a wide audience of investors, consumers, media outlets and the general public by leveraging our expansive dissemination network of more than 5,000 key syndication outlets. PNW is committed to delivering improved visibility and brand recognition to companies operating in the emerging markets of psychedelics.
To receive instant SMS alerts, text “Groovy” to 21000 (U.S. Mobile Phones Only)
For more information please visit https://www.PsychedelicNewsWire.com
Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.PsychedelicNewsWire.com/Disclaimer
Do you have questions or are you interested in working with PNW? Ask our Editor
PsychedelicNewsWire (PNW)
San Francisco, California
www.PsychedelicNewsWire.com
415.949.5050 Office
Editor@PsychedelicWire.com
PsychedelicNewsWire is part of the InvestorBrandNetwork.
